LGK974 No Further a Mystery
Given that authorized in 2014, tucidinostat was considered as a 2nd-line and subsequent therapy for PTCL people in China. Clinical trials and preclinical scientific tests in numerous hematological malignancies and good tumors is in progress.In summary, although the scientific result of tucidinostat to the treatment method of PTCL has actually been